ULURU Inc. Announces the Launch Plan for Alt...(benefits are ideally suited to the burn ...),Health
Navigation Links
ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
Date:5/8/2008
benefits are ideally suited to the burn care market. The ease of application and removal and reduced need for dressing changes will enhance patient comfort. Once Altrazeal(TM) has been established in the burn market, additional efforts will be directed at wound care centers and the use of Altrazeal(TM) for the treatment and management of chronic wounds.
Commenting on the launch of Altrazeal(TM), Renaat Van Den Hooff, Executive Vice President-Operations of ULURU commented, "This is a major milestone in the development of the Company and a significant achievement, having overcome all the challenges associated with production scale-up. It is an exciting period for the Company as we build our sales force and commercial infrastructure. The market research and response from physicians and nurses gives us a high level of confidence that Altrazeal(TM) will be perceived as a transformational innovation in the wound care market. We believe that by rapidly establishing key opinion leader support we can quickly build a solid foundation from which we plan to penetrate the burn market."
The Company's focus is to add two products to our wound care franchise in 2009. The first product under development is an antimicrobial dressing containing silver. The necessary toxicology studies for submission of a 510k regulatory application are nearing completion and production scale-up for blending the product has commenced. We expect to file a 510k application with the FDA in the third quarter of 2008, with the product launch being planned for first quarter 2009.
Mr. Van den Hooff continued, "Adding a silver product to our wound care franchise is very important as infection control is a high priority for physicians. Bringing this product to market as soon as possible is our highest product development priority."
About ULURU Inc.:
ULURU Inc. is an emerging specialty pharmaceutical company focused on
the development of a portfolio of wound management, plasti
'/>"/>
| SOURCE ULURU Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
2. ULURU Inc. Announces Odd-Lot Buy Back Offer
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
4. ULURU Inc. Reports Third Quarter 2007 Results
5. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
6. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
9. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
10. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
11. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
Post Your Comments:
(Date:12/2/2008)..., Dec. 2 To support medication-sa...um (UHC) and Safecor Health, LLC, announced today ...ment for bar-coded pharmaceutical repackaging serv..., , "UHC is very pleased with the addition ...f agreements and is excited to embark on a partner...
(Date:12/2/2008)...Prevention, Shedding, or Sharing Costs as Key , ...-- A New Center for State and Local Government Exc...etiree health care plans and their need to contain...rican States examines how state administrators pe...its to central human resources (HR) goals; how the...
(Date:12/2/2008)...o 70 Cities and Regions by 2010 , , PRINCET... first investment of a new $44 million initiative,...rded grants of up to $400,000 to nine communities ...s for its most ambitious effort yet to reverse the...ids, Healthy Communities will support local actio...
(Date:12/2/2008)... aprotinin, a drug commonly used to control blood ...ared with lysine analogues, according to a study ...e published in the January 20th issue of CMAJ . ... panel will meet to decide on aprotinin use. The s...ting. , The study, a systematic review of 49 ra...
Breaking Medicine News(10 mins):Health News:UHC and Safecor Health Announce Multi-Year Agreement for Repackaging Bar-Coded Medications 2Health News:States View Limits on Retiree Health Benefits 2Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 2Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 3Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 4[0] UHC and Safecor Health Announce Multi-Year Agreement for Repackaging Bar-Coded Medications[0] States View Limits on Retiree Health Benefits[0] Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity[0] Risk of death may be higher with drug commonly used during cardiac surgery
...o scientists Vivian Cheung and Warren Ewens from t...isorders that are recessively inherited. Gene exp...ould differ significantly and this new diagnostic ...echnology to identify differences in genome-wide e...
...ing cattle with many growth hormones that are extr... among EU nations that import beef, necessitating ...expert and a pharmaceutical chemist, John Verrall ...ts of consuming beef from cattle that have been in...
...ers, a woman who lost her husband to AIDS and is n...in her Bihar home. Premila Devi, 40, from Tilaei ...ing into a well Saturday, just a few months after ...d of AIDS. "She was upset by the way her family m...
... babies’ to be overweight, which is thought to be ...’ diet during pregnancy. A study that analyzed nea... UK, the Scottish babies’ weight scored the highes...tuation can be remedied if pregnant women were mad...
Other Medicine News:Health News:New Diagnostic Tool Uncovered Gene Expression Patterns in Recessive Genetic Disorders 2(Date:12/1/2008)...ARD, Denmark, December 1 ...with the intent to procure an MVA-based,third ge...ment Services,Canada, on behalf of the Canadian D...ract to Bavarian Nordic for the delivery of IMVAMU... use IMVAMUNE(R) as part of the,country,s bio-pre...
(Date:11/30/2008)...ec. 1 Abnormalities in ...in children with autism spectrum disorder by using...y presented today at the annual meeting of the Rad..., "Using MEG, we can record the tiny magnetic fi...aid Timothy Roberts, Ph.D., vice chair of research...
(Date:11/26/2008)...information density, automation and intelligent cl...trasound to an all new level , , CHICAGO, I...Healthcare ( www.siemens.com/healthcare ) highli...Scanner (ABVS)(1), the world,s first multi-use, a...4th Scientific Assembly and Annual Meeting of the ...
(Date:11/25/2008)...FRANCISCO, Calif., Nov. 25 Proteol...nt of novel therapeutics that target,protein degr..., today,announced that data from two ongoing Phas...eloma will be presented at the upcoming 50th Annua...ASH). Carfilzomib is the first in a new class,of...
Breaking Medicine Technology:The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Ohio Company to Debut Turnkey Marketing Material During Florida National Dental Convention 20824 1Ohio Company to Debut Turnkey Marketing Material During Florida National Dental Convention 20824 2Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen Deprivation Therapy 2287 1Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen Deprivation Therapy 2287 2Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen Deprivation Therapy 2287 3Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen Deprivation Therapy 2287 4Bamboo instant houses will soon shelter Sichuan quake victims 3504 1Bamboo instant houses will soon shelter Sichuan quake victims 3504 2Is tap water safe for expectant mothers 3F 20821 1Is tap water safe for expectant mothers 3F 20821 2[0] The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness[0] Brain Waves Show Sound Processing Abnormalities in Autistic Children[0] Siemens Introduces New Standard of Care for Breast Ultrasound[1] Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
...therapeutic approach for the treatment,of early an... 2007 /PRNewswire-FirstCall/ - AEterna,Zentaris In...,focused on endocrine therapy and oncology, today ...ts growth hormone-releasing,hormone (GHRH) antagon...ciation for Cancer Research (AACR) Annual Meeting ...
...pr 16, 2007 - Arsenic, a naturally,occurring eleme...r,2,000 years, and even now remains a venerable co..., Today, due in measure to the efforts of investig...ancer Research Foundation,s,(SWCRF) "Institute Wit...ed in therapy for the treatment of certain types o...
Other Medicine Technology:AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 3Research Supported by Samuel Waxman Cancer Research Foundation,Discovers Mode of Action of Arsenic-Based Drugs in Destroying,Cancer Cells 2Research Supported by Samuel Waxman Cancer Research Foundation,Discovers Mode of Action of Arsenic-Based Drugs in Destroying,Cancer Cells 3For determination of HDL-cholesterol in serum and plasma. For Hitachi 717. Specific immunochemical inhibition of non-HDL-lipoproteins. Excellent correlation with established reference methods. Endpoi
Cholesterol/HDL Standard 50 mg/dl.
Intended for the in vitro precipitation of very low density and low density lipoproteins in serum or plasma. Single vial, dry powder precipitating reagent. Total cholesterol reagent not included.
Ready to use liquid single reagent for automated chemistry analyzers. Linearity to 1000 mmol/L
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |